Newly developed retatrutide, a twin -action treatment targeting equally GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Early clinical research have revealed substantial losses in physical mass and improvements in health markers for people with excess weight . Experts believe this novel approach may si